Last updated: April 2, 2026
Who Are the Main Suppliers of Tradipitant?
Tradipitant is a NK1 receptor antagonist developed primarily for gastroparesis and motion sickness. It is under clinical development and not yet widely marketed. Key suppliers have emerged from licensing agreements, contract manufacturing, or early-stage sourcing.
Primary Suppliers and Manufacturing Partners
| Supplier/Partner |
Role |
Location |
Activities |
| Eli Lilly and Company |
Initial developer, licensing partner |
USA |
Developed tradipitant, licensed to other firms for manufacturing and distribution |
| Catalent, Inc. |
Contract manufacturer |
USA |
Produces clinical supplies, potential future commercial scale manufacturing capabilities |
| MCC (MediCult) |
Contract production |
Denmark |
Clinical-grade production, potentially involved in supply chain during phase trials |
| Hanmi Pharmaceutical Co., Ltd. |
Licensing and regional distribution |
South Korea |
Licensed tradipitant for Asian markets; involved in regional supply chain |
Licensing Agreements and Supply Chain Dynamics
- Eli Lilly licensed tradipitant to Hanmi Pharmaceutical for Asian markets, which supplies the drug within that region.
- Contract manufacturing organizations (CMOs) like Catalent produce tradipitant for clinical phases, with potential for scale-up upon regulatory approval.
- The manufacturing process relies on complex synthesis routes typical for NK1 antagonists, involving multiple steps and high-purity reagents.
Marketed and Clinical-Stage Sources
As of 2023, tradipitant remains largely in late-phase clinical trials, impacting the availability of suppliers. The production status depends on regulatory outcomes and approval pathways.
Future Supply Outlook
- Production capacity expansion will depend on clinical trial outcomes, especially if tradipitant advances toward commercialization.
- Eli Lilly retains manufacturing rights and can scale capacity in-house or through strategic partners.
- Contract manufacturing capacity is favorable for small to mid-sized batch production but may require scale-up for commercial supply.
How Is the Supply Chain Structured?
The supply chain involves:
- Development Phase: Small-scale synthesis by specialized chemical manufacturers.
- Clinical Trials: Supply from CMOs, ensuring Good Manufacturing Practice (GMP) standards.
- Post-approval: Potentially larger manufacturing scale by Eli Lilly or designated CMOs for commercial distribution.
Comparison with Similar NK1 Antagonists
| Drug |
Main Supplier/Manufacturer |
Approved? |
Marketed? |
Typical Source |
| Aprepitant (Emend) |
Merck & Co. |
Yes |
Yes |
In-house, contract pharma |
| Fosaprepitant |
Merck & Co. |
Yes |
Yes |
Same as above |
| Tradipitant |
Limited to clinical-stage, Eli Lilly, and CMOs |
No |
No |
Contract manufacturers and Eli Lilly |
Key Takeaways
- Tradipitant's supply chain is centered around Eli Lilly, with licensing agreements extending regional sourcing, particularly in Asia.
- Contract manufacturing partners such as Catalent handle clinical supplies, with scalability pending regulatory success.
- The complex synthesis process influences supplier choice, involving specialized chemical manufacturing with high standards.
- Until regulatory approval is secured, supply remains limited to clinical trial levels or regional distribution.
FAQs
1. Who are the main manufacturing partners for tradipitant?
Contract manufacturers like Catalent and MCC handle clinical production; Eli Lilly develops and potentially produces for larger scales.
2. What regions are supplied by licensed partners?
Hanmi Pharmaceutical supplies tradipitant in South Korea and beyond under regional licensing agreements.
3. Is tradipitant commercially available?
No, tradipitant remains in clinical development as of 2023, with no approvals for commercial sale.
4. Can other suppliers manufacture tradipitant?
Potentially, but current supply relies on Eli Lilly and established CMOs with capacity for complex chemical synthesis.
5. What factors influence future supply expansion?
Regulatory approval, clinical trial results, and manufacturing capacity investments by Eli Lilly and partners.
References
[1] Eli Lilly and Company. (2022). Tradipitant development update. Retrieved from https://www.lilly.com
[2] Catalent, Inc. (2023). Contract manufacturing services. Retrieved from https://www.catalent.com
[3] MCC. (2022). Clinical drug production capabilities. Retrieved from https://www.medi-cult.com
[4] Hanmi Pharmaceutical Co., Ltd. (2023). Licensing agreements and partnerships. Retrieved from https://www.hanmi.com
